« Return to archives | Clinical Intelligence

Tasimelteon could reset body’s clock in sleep-wake disorder

Friday, January 27, 2012 02:17 PM

Vanda Pharmaceuticals’ compound tasimelteon has shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder. Tasimelteon is a circadian regulator in development for the treatment of the sleep-wake disorder in completely blind individuals with no light perception.

This observation was made in four patients during the initial run-in segment of the RESET study.  RESET is a phase III study of the maintenance effect of tasimelteon in the treatment of Non-24-Hour Sleep-Wake Disorder, which affects over 50% of all completely blind individuals in the U.S. Vanda intends to enroll a total of 20 tasimelteon responders in this study.

Circadian regulation is necessary for the treatment of the disorder and is predictive of a beneficial effect on both nighttime sleep and daytime naps. While light resets the body clock in sighted individuals, keeping it synchronized with the 24-hour day, this effect is lost in completely blind individuals with no light perception.

Vanda is currently studying the efficacy of tasimelteon in Non-24-Hour Sleep-Wake Disorder in two phase III studies, SET and RESET, which are ongoing and expected to be completed by the end of 2012.

Share:          
CWWeekly

February 21

Survey: Sponsors, CROs making changes to their business models to demonstrate value to payers

Cegedim ranks top pharma companies on their use of, and success with, social media

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

February

Anticipating the rise of virtual drug development
With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have...

Closing investigative site operations a complex process
In light of the shrinking investigative site landscape, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into...

Eye On Shire
Shire is a rapidly growing, global specialty biopharmaceutical company, directly marketing its products in over 50 countries...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.